Kymera Investor Day Presentation Deck
Pathway Program
IL-1R/TLR
JAK/STAT
p53
Collaboration
Discovery
Pipeline
Collaboration
IRAK4
IRAKIMID
(IRAK4, Ikaros, Aiolos)
STAT3
STAT3
MDM2
Confidential
Kymera's Pipeline of Novel Protein Degraders
Indication(s)
Multiple Immuno-
inflammatory Diseases:
HS, AD, RA
others
MYD88MT Tumors
Liquid & Solid Tumors
Autoimmune &
Fibrotic Diseases
Liquid & Solid Tumors
Confidential
Several Discovery Programs
6 Undisclosed Programs
Discovery
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
IND Enabling
Multiple molecules staged as
potential back ups if needed
00
KT-474
KT-253
KT-413
KT-333
Phase 1
*Option to participate equally in the development and commercialization of Sanofi-partnered programs in the US
Multiple programs in immune-inflammatory and
oncology indications to deliver ≥ 1 IND/year
6 targets in 5 disease areas outside of
immunology-inflammation and oncology
KYMERA R&D DAY - December 16th, 2021
Phases 2/3
=
Oncology
NEW
Next Milestone Rights*
KYMERA
Patients POB
mid-22
POM: 2022
POM: 2022
IND: 2H22
≥ 1 DC: 2H22
= Immunology-Inflammation
SANOFI
KYMERA
KYMERA
KYMERA
KYMERA
K SANOFI
KYMERA
VERTEX
PAGE 12View entire presentation